469 related articles for article (PubMed ID: 24997481)
1. A chitosan-graft-PEI-candesartan conjugate for targeted co-delivery of drug and gene in anti-angiogenesis cancer therapy.
Bao X; Wang W; Wang C; Wang Y; Zhou J; Ding Y; Wang X; Jin Y
Biomaterials; 2014 Sep; 35(29):8450-66. PubMed ID: 24997481
[TBL] [Abstract][Full Text] [Related]
2. Synergistic Suppression of Tumor Angiogenesis by the Co-delivering of Vascular Endothelial Growth Factor Targeted siRNA and Candesartan Mediated by Functionalized Carbon Nanovectors.
Ding X; Su Y; Wang C; Zhang F; Chen K; Wang Y; Li M; Wang W
ACS Appl Mater Interfaces; 2017 Jul; 9(28):23353-23369. PubMed ID: 28617574
[TBL] [Abstract][Full Text] [Related]
3. A precision-guided MWNT mediated reawakening the sunk synergy in RAS for anti-angiogenesis lung cancer therapy.
Su Y; Hu Y; Wang Y; Xu X; Yuan Y; Li Y; Wang Z; Chen K; Zhang F; Ding X; Li M; Zhou J; Liu Y; Wang W
Biomaterials; 2017 Sep; 139():75-90. PubMed ID: 28595131
[TBL] [Abstract][Full Text] [Related]
4. Captopril-polyethyleneimine conjugate modified gold nanoparticles for co-delivery of drug and gene in anti-angiogenesis breast cancer therapy.
Li M; Li Y; Huang X; Lu X
J Biomater Sci Polym Ed; 2015; 26(13):813-27. PubMed ID: 26166244
[TBL] [Abstract][Full Text] [Related]
5. Novel biotinylated chitosan-graft-polyethyleneimine copolymer as a targeted non-viral vector for anti-EGF receptor siRNA delivery in cancer cells.
Darvishi MH; Nomani A; Amini M; Shokrgozar MA; Dinarvand R
Int J Pharm; 2013 Nov; 456(2):408-16. PubMed ID: 24012865
[TBL] [Abstract][Full Text] [Related]
6. Versatile reticular polyethylenimine derivative-mediated targeted drug and gene codelivery for tumor therapy.
Ding X; Wang W; Wang Y; Bao X; Wang Y; Wang C; Chen J; Zhang F; Zhou J
Mol Pharm; 2014 Oct; 11(10):3307-21. PubMed ID: 25058017
[TBL] [Abstract][Full Text] [Related]
7. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination.
Suganuma T; Ino K; Shibata K; Kajiyama H; Nagasaka T; Mizutani S; Kikkawa F
Clin Cancer Res; 2005 Apr; 11(7):2686-94. PubMed ID: 15814650
[TBL] [Abstract][Full Text] [Related]
8. Supramolecular self-assembly forming a multifunctional synergistic system for targeted co-delivery of gene and drug.
Zhao F; Yin H; Li J
Biomaterials; 2014 Jan; 35(3):1050-62. PubMed ID: 24189097
[TBL] [Abstract][Full Text] [Related]
9. A Biomimic Reconstituted High-Density-Lipoprotein-Based Drug and p53 Gene Co-delivery System for Effective Antiangiogenesis Therapy of Bladder Cancer.
Ouyang Q; Duan Z; Jiao G; Lei J
Nanoscale Res Lett; 2015 Dec; 10(1):965. PubMed ID: 26156217
[TBL] [Abstract][Full Text] [Related]
10. Suppression of tumor growth in H-ras12V liver cancer mice by delivery of programmed cell death protein 4 using galactosylated poly(ethylene glycol)-chitosan-graft-spermine.
Kim JH; Minai-Tehrani A; Kim YK; Shin JY; Hong SH; Kim HJ; Lee HD; Chang SH; Yu KN; Bang YB; Cho CS; Yoon TJ; Yu DY; Jiang HL; Cho MH
Biomaterials; 2012 Feb; 33(6):1894-902. PubMed ID: 22153867
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer.
Kosugi M; Miyajima A; Kikuchi E; Horiguchi Y; Murai M
Clin Cancer Res; 2006 May; 12(9):2888-93. PubMed ID: 16675585
[TBL] [Abstract][Full Text] [Related]
12. Candesartan attenuates angiogenesis in hepatocellular carcinoma via downregulating AT1R/VEGF pathway.
Fan F; Tian C; Tao L; Wu H; Liu Z; Shen C; Jiang G; Lu Y
Biomed Pharmacother; 2016 Oct; 83():704-711. PubMed ID: 27470571
[TBL] [Abstract][Full Text] [Related]
13. A dual-targeting drug co-delivery system for tumor chemo- and gene combined therapy.
Zhang F; Li M; Su Y; Zhou J; Wang W
Mater Sci Eng C Mater Biol Appl; 2016 Jul; 64():208-218. PubMed ID: 27127046
[TBL] [Abstract][Full Text] [Related]
14. Chitosan-graft-(PEI-β-cyclodextrin) copolymers and their supramolecular PEGylation for DNA and siRNA delivery.
Ping Y; Liu C; Zhang Z; Liu KL; Chen J; Li J
Biomaterials; 2011 Nov; 32(32):8328-41. PubMed ID: 21840593
[TBL] [Abstract][Full Text] [Related]
15. Linear polyethylenimine-graft-chitosan copolymers as efficient DNA/siRNA delivery vectors in vitro and in vivo.
Tripathi SK; Goyal R; Kumar P; Gupta KC
Nanomedicine; 2012 Apr; 8(3):337-45. PubMed ID: 21756861
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer.
Kosaka T; Miyajima A; Takayama E; Kikuchi E; Nakashima J; Ohigashi T; Asano T; Sakamoto M; Okita H; Murai M; Hayakawa M
Prostate; 2007 Jan; 67(1):41-9. PubMed ID: 17044086
[TBL] [Abstract][Full Text] [Related]
17. Target gene delivery from targeting ligand conjugated chitosan-PEI copolymer for cancer therapy.
Nam JP; Nah JW
Carbohydr Polym; 2016 Jan; 135():153-61. PubMed ID: 26453863
[TBL] [Abstract][Full Text] [Related]
18. Hepatocyte-targeted gene transfection of galactosylated chitosan-graft low molecular polyethyleneimine/DNA complexes.
Tan P; Li M; Wang Y; Feng D
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 May; 36(5):369-80. PubMed ID: 21685690
[TBL] [Abstract][Full Text] [Related]
19. Effect of angiotensin II type 1 receptor antagonist on tumor growth and angiogenesis in a xenograft model of human bladder cancer.
Kosugi M; Miyajima A; Kikuchi E; Kosaka T; Horiguchi Y; Murai M
Hum Cell; 2007 Feb; 20(1):1-9. PubMed ID: 17506771
[TBL] [Abstract][Full Text] [Related]
20. Galactosylated chitosan-graft-polyethylenimine as a gene carrier for hepatocyte targeting.
Jiang HL; Kwon JT; Kim YK; Kim EM; Arote R; Jeong HJ; Nah JW; Choi YJ; Akaike T; Cho MH; Cho CS
Gene Ther; 2007 Oct; 14(19):1389-98. PubMed ID: 17637795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
